The FDA Offers a Controversial Solution to the Biosimilars Name Game
Friday, August 28, 2015
Source: Fierce Biotech
The industry has been wrestling for years now over naming the first wave of biosimilars building on the coast of the American drug industry. A lot of companies that develop biosimilars, and that group includes some major corporations, wanted to use the same generic--or nonproprietary--names as the branded drugs, looking to make it easier to carve their way into some blockbuster drug franchises. And a lot of those major brand name franchisors wanted something completely different, forcing the biosimilar crowd to market these drugs like a new arrival--a costly and time consuming affair that would help limit any discounting that may have to come after biosimilar competition hits.